title: Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.
abstract: Hypoxia restricts cell proliferation and cell cycle progression at the G1/S interface but at least a subpopulation of carcinoma cells can escape the restriction. In carcinoma hypoxia may in fact select for cells with enhanced hypoxic survival and increased aggressiveness. The cellular oxygen sensors HIF proline hydroxylases (PHDs) adapt the cellular functions to lowered environmental oxygen tension. PHD3 isoform has shown the strongest hypoxic upregulation among the family members. We detected a strong PHD3 mRNA expression in tumors of head and neck squamous cell carcinoma (HNSCC). The PHD3 expression associated with expression of hypoxic marker gene. Using siRNA in cell lines derived from HNSCC we show that specific inhibition of PHD3 expression in carcinoma cells caused reduced cell survival in hypoxia. The loss of PHD3, but not that of PHD2, led to marked cell number reduction. Although caspase-3 was activated at early hypoxia no induction of apoptosis was detected. However, hypoxic PHD3 inhibition caused a block in cell cycle progression. Cell population in G1 phase was increased and the population in S phase reduced demonstrating a block in G1 to S transition under PHD3 inhibition. In line with this, the level of hyperphosphorylated retinoblastoma protein Rb was reduced by PHD3 knock-down in hypoxia. PHD3 loss led to increase in cyclin-dependent kinase inhibitor p27 expression but not that of p21 or p16. The data demonstrated that increased PHD3 expression under hypoxia enhances cell cycle progression and survival of carcinoma cells.
authors.affiliation: Turku Centre for Biotechnology, Turku University and Åbo Akademi University, Turku, Finland.
authors.forename: Heidi
authors.initials: H
authors.lastname: Högel
authors.forename: Krista
authors.initials: K
authors.lastname: Rantanen
authors.forename: Terhi
authors.initials: T
authors.lastname: Jokilehto
authors.forename: Reidar
authors.initials: R
authors.lastname: Grenman
authors.forename: Panu M
authors.initials: PM
authors.lastname: Jaakkola
mesh_terms: D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D049308:Dioxygenases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000502:physiology*; D016193:G1 Phase / Q000187:drug effects; D006258:Head and Neck Neoplasms / Q000188:drug therapy / Q000473:pathology*; D006801:Humans; D000860:Hypoxia / Q000235:genetics*; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases; D011393:Procollagen-Proline Dioxygenase / Q000235:genetics / Q000502:physiology; D034741:RNA, Small Interfering / Q000494:pharmacology; D016196:S Phase / Q000187:drug effects; D000077195:Squamous Cell Carcinoma of Head and Neck
chemical_list: D034741:RNA, Small Interfering; D049308:Dioxygenases; C490190:EGLN1 protein, human; D011393:Procollagen-Proline Dioxygenase; C488894:EGLN3 protein, human; D064799:Hypoxia-Inducible Factor-Proline Dioxygenases
references.citation: Nat Rev Cancer. 2003 Oct;3(10):721-32
references.pmid: 13130303
references.citation: J Cell Mol Med. 2009 Oct;13(10):4104-12
references.pmid: 19691672
references.citation: J Biol Chem. 2003 Dec 5;278(49):48690-5
references.pmid: 14506252
references.citation: EMBO J. 2004 May 5;23(9):1949-56
references.pmid: 15071503
references.citation: J Neurochem. 1999 Jul;73(1):429-32
references.pmid: 10386996
references.citation: Arch Otolaryngol Head Neck Surg. 1992 May;118(5):542-7
references.pmid: 1571132
references.citation: Science. 2001 Apr 20;292(5516):468-72
references.pmid: 11292861
references.citation: Cancer Cell. 2009 Nov 6;16(5):413-24
references.pmid: 19878873
references.citation: Cell. 1989 Sep 22;58(6):1193-8
references.pmid: 2673546
references.citation: Eur J Immunol. 1998 Mar;28(3):891-900
references.pmid: 9541584
references.citation: Biochem J. 2004 Aug 1;381(Pt 3):761-7
references.pmid: 15104534
references.citation: Oncogene. 1993 Feb;8(2):331-9
references.pmid: 8426741
references.citation: Nature. 1999 May 20;399(6733):271-5
references.pmid: 10353251
references.citation: Clin Cancer Res. 2006 Feb 15;12(4):1080-7
references.pmid: 16489060
references.citation: Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5510-4
references.pmid: 7539918
references.citation: Genes Dev. 1993 May;7(5):812-21
references.pmid: 8491378
references.citation: Int J Radiat Oncol Biol Phys. 1984 Aug;10(8):1275-80
references.pmid: 6469750
references.citation: Mol Cell Biol. 2001 Feb;21(4):1196-206
references.pmid: 11158306
references.citation: Mol Cell. 2008 May 23;30(4):393-402
references.pmid: 18498744
references.citation: J Cell Biochem. 2004 Jun 1;92(3):491-501
references.pmid: 15156561
references.citation: J Biol Chem. 2001 Mar 16;276(11):7919-26
references.pmid: 11112789
references.citation: J Cell Mol Med. 2010 Apr;14(4):758-70
references.pmid: 20178464
references.citation: J Biol Chem. 2003 Aug 15;278(33):30772-80
references.pmid: 12788921
references.citation: Nat Rev Cancer. 2002 Jan;2(1):38-47
references.pmid: 11902584
references.citation: Proc Natl Acad Sci U S A. 2008 Mar 25;105(12):4745-50
references.pmid: 18347341
references.citation: J Biol Chem. 2004 Sep 10;279(37):38458-65
references.pmid: 15247232
references.citation: Cancer Res. 2007 May 15;67(10):4605-19
references.pmid: 17510386
references.citation: EMBO J. 2003 Aug 15;22(16):4082-90
references.pmid: 12912907
references.citation: Cell Prolif. 1991 Mar;24(2):127-41
references.pmid: 2009318
references.citation: Exp Cell Res. 2010 Oct 15;316(17):2871-82
references.pmid: 20599946
references.citation: Science. 2001 Apr 20;292(5516):464-8
references.pmid: 11292862
references.citation: Cell. 2001 Oct 5;107(1):43-54
references.pmid: 11595184
references.citation: Mol Cell Biol. 2003 Jan;23(1):359-69
references.pmid: 12482987
references.citation: Cell. 1995 May 5;81(3):323-30
references.pmid: 7736585
references.citation: Mol Cell. 2005 Mar 18;17(6):793-803
references.pmid: 15780936
references.citation: Br J Cancer. 1983 Dec;48(6):809-17
references.pmid: 6652020
references.citation: Science. 2001 Nov 9;294(5545):1337-40
references.pmid: 11598268
references.citation: Nature. 1996 Jan 4;379(6560):88-91
references.pmid: 8538748
references.citation: Cancer Res. 2010 Jan 1;70(1):357-66
references.pmid: 20028863
references.citation: Oncogene. 2003 May 8;22(18):2728-38
references.pmid: 12743597
references.citation: Cell. 1989 Sep 22;58(6):1097-105
references.pmid: 2673543
references.citation: Cancer Res. 2010 Jul 15;70(14):5984-93
references.pmid: 20551054
references.citation: Mol Biol Cell. 2008 May;19(5):2231-40
references.pmid: 18337469
references.citation: Br J Cancer. 2010 Nov 9;103(10):1571-9
references.pmid: 20978507
references.citation: Exp Cell Res. 2002 Aug 1;278(1):53-60
references.pmid: 12126957
references.citation: Exp Cell Res. 2010 Apr 15;316(7):1169-78
references.pmid: 20156434
references.citation: J Biol Chem. 2003 Oct 3;278(40):38183-7
references.pmid: 12876291
references.citation: Cancer Cell. 2005 Aug;8(2):155-67
references.pmid: 16098468
references.citation: Nat Rev Cancer. 2002 Sep;2(9):673-82
references.pmid: 12209156
references.citation: Proc Natl Acad Sci U S A. 1988 Dec;85(24):9533-7
references.pmid: 3200838
references.citation: Nat Rev Cancer. 2008 Apr;8(4):253-67
references.pmid: 18354415
references.citation: Genes Dev. 2008 Apr 1;22(7):884-93
references.pmid: 18334619